KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

RIYADH, Saudi Arabia, May 10, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH&RC) has experienced a year of achievements across its three Centres of Excellence—Oncology, Genomics, and Transplantation.

KFSH&RC’s Oncology Centre of Excellence continues to lead the fight against the disease in the Kingdom. This year alone, the centre has treated 25% of all cancer cases in Saudi Arabia, achieving a 50% overall recovery rate and up to 90% recovery in leukemia cases. With almost five decades of service, the centre’s commitment to providing advanced cancer treatments is evident in its adoption of technologies such as CAR T-cell therapy and liquid biopsy, which provide less invasive alternatives to traditional methods, along with extensive bone marrow transplants, and revolutionary techniques like Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

Notably, KFSH&RC has achieved a milestone by completing over 100 CAR T-cell therapy procedures, a novel treatment that genetically modifies a patient’s immune cells to fight cancer. This achievement puts it on par with renowned institutions that are also advancing CAR-T cell therapy for various blood cancers and exploring expanded applications through clinical trials and new treatment protocols. Furthermore, the centre’s focus on pediatric oncology boasts a 97% five-year survival rate for renal tumors and a 92% survival rate for acute lymphoblastic leukemia in children.

With rapid advancements in genomic medicine, KFSH&RC is adopting next-generation sequencing technologies into patient care in its Genomic Centre, revolutionizing local and regional approaches to disease management. KFSH&RC’s discovery of the bacterial strain Stenotrophomonas Riyadhensis, facilitated by whole-genome sequencing (WGS) technology, has contributed to our understanding of bacterial antibiotic resistance mechanisms. With 15,698 patient visits and over 5,658 whole genomes completed in 2023, the centre ensures that prevention, diagnosis, and treatment are precise and personalized.

KFSH&RC’s Organ Transplant Centre of Excellence (OTCoE) continues to be the primary contributor to organ transplantation activities in the Kingdom, accounting for 65% of all transplants performed nationally. In 2023, OTCoE performed 1,092 solid organ transplants, including the world’s first fully robotic liver transplant— where doctors employed robotic technology to conduct surgery on both patient and donor — an achievement that places the centre at the forefront of global transplantation practices.

As KFSH&RC continues to push the boundaries of what is possible in medical science, its efforts not only inspire but also significantly impact the global healthcare community, reaffirming its role as a leader in medical innovation and specialized healthcare.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally for the second consecutive year. Additionally, in 2024, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

CONTACT INFORMATION

For more information, please contact:

Mr. Essam Al-Zahrani, Acting Media Affairs Head, 0555254429

Mr. Abdullah Al-Aown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e99afd2f-d5c6-400e-9290-26b36a580bee

GlobeNewswire Distribution ID 9115490

Curia e Carterra Fazem Parceria em Simpósio para o Avanço da Pesquisa Biotecnológica do Noroeste do Pacífico

ALBANY, N.Y. e SALT LAKE CITY, May 10, 2024 (GLOBE NEWSWIRE) — A Curia, uma organização líder em contratos de pesquisa, desenvolvimento e fabricação, e a Carterra Inc., líder mundial em descoberta de medicamentos de moléculas pequenas e anticorpos de alto rendimento sem rótulos, anunciaram hoje sua parceria para a realização de um simpósio de produtos biológicos de alto rendimento previsto para 31 de maio no Residence Inn do Marriott em Seattle, Washington.

O objetivo da colaboração é promover o crescente foco em biotecnologia na região Noroeste do Pacífico dos EUA e Canadá. O simpósio reunirá todos os níveis de liderança científica das comunidades de biotecnologia e farmacêutica.

“Estamos muito entusiasmados com a parceria com a Carterra para organizar este simpósio de descoberta de anticorpos, reunindo a comunidade de biotecnologia do Noroeste do Pacífico e compartilhando os mais recentes avanços na descoberta de anticorpos”, disse Steve Lavezoli, Vice-Presidente de Produtos Biológicos da Curia. “Também estamos prontos para compartilhar nossos fluxos de trabalho de descoberta ideal de anticorpos de alta qualidade e acelerados para a primeira descoberta, desenvolvimento e fabricação clínica de anticorpos humanos. Os anticorpos descobertos e/ou projetados com a tecnologia de plataforma da Curia são para a área de clínica e temos mais de 230 campanhas bem-sucedidas de descoberta de anticorpos realizadas para a comunidade de biotecnologia.”

A velocidade, a experiência científica e a eficiência podem superar as altas taxas de atrito da descoberta precoce de anticorpos e alcançar a primeira distribuição no mercado de novas terapêuticas. O simpósio destacará a plataforma tecnológica e os serviços integrados da Curia com foco no desenvolvimento de sistemas aprimorados de camundongos para geração de anticorpos e triagem de células B únicas de alto rendimento. A combinação de sequenciamento de próxima geração (NGS) e produção recombinante rápida de quantidades de miligrama para grama de anticorpo monoclonal purificado (mAb) acelera significativamente a identificação de condutores candidatos ao desenvolvimento.

Desde 2017, a Carterra tem vendido seu potente biossensor de alto rendimento LSA® para analisar e caracterizar anticorpos com Ressonância Plasmônica de Superfície (SPR). Com o lançamento da sua plataforma LSAXT no ano passado, a Carterra passou a oferecer produtos que podem realizar análises de moléculas pequenas, bem como a descoberta de anticorpos. A plataforma LSA foi destaque em vários artigos revisados por pares em Science, Nature e Cell, detalhando o caminho de várias terapêuticas que estão entrando em ensaios clínicos. No simpósio, vários cientistas líderes em biofarmacêutica compartilharão suas ideias sobre suas áreas específicas de descoberta de medicamentos e destacarão o impacto transformador da integração da tecnologia HT-SPR, IA/ML e outras novas tecnologias.

“Estamos entusiasmados com a nossa parceria com a Curia no nosso simpósio. Os simpósios Carterra são eventos científicos que organizamos todos os anos nos EUA e na Europa”, disse Chris M. Silva, Vice-Presidente de Marketing e Produtos da Carterra. “Esses simpósios nos ajudam a compartilhar os mais recentes avanços tecnológicos e dados importantes gerados a partir dos fluxos de trabalho de cientistas que usam as plataformas sem rótulos da Carterra. A nossa entrada no noroeste do Pacífico é uma oportunidade para aumentar o entendimento mais profundo da tecnologia para produtos farmacêuticos e biotecnológicos nesta região.”

Clique aqui para confirmar presença no evento. É necessário inscrição pois temos vagas limitadas.

Sobre a Curia:
A Curia é uma Organização de Desenvolvimento e Fabricação de Contratos (CDMO) com mais de 30 anos de experiência, uma rede integrada de 27 locais globais e mais de 3.500 funcionários em parceria com clientes biofarmacêuticos para levar ao mercado terapias que mudam a vida. Nossas ofertas de produtos biológicos e pequenas moléculas abrangem a descoberta através da comercialização, com capacidades regulatórias e analíticas integradas. Nossos especialistas científicos e de processos, e instalações de última geração oferecem a melhor experiência em fabricação de medicamentos e produtos farmacêuticos. Da curiosidade à cura, proporcionamos todas as etapas para a melhoria da vida dos pacientes. Visite-nos em curiaglobal.com.

Sobre a Carterra, Inc.:
A Carterra, Inc. é uma empresa privada. Sua tecnologia HT-SPR fornece aos clientes de descoberta de medicamentos de moléculas grandes e pequenas, o rendimento e a funcionalidade de triagem e caracterização que são dimensionados com aplicativos de nível ômico, condensando meses de trabalho em dias. Nossas soluções viabilizaram múltiplas terapias e pesquisas inovadoras e ajudaram pesquisadores acadêmicos e translacionais e empresas biofarmacêuticas em oncologia, imunologia, neurociência e muito mais.  A Carterra está sediada em Salt Lake City, Utah, e tem Centros de Experiência do Cliente em São Francisco, Salt Lake City, Boston, Manchester, Inglaterra e Munique, Alemanha. Os produtos Carterra estão disponíveis na Ásia-Pacífico e na Oceania através do nosso distribuidor exclusivo, Revvity. Para mais informação, visite www.carterra-bio.com ou conecte-se conosco no LinkedIn ou X (Twitter).

Contato da Curia:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Contato para Mídia da Carterra:
Cheri Salazar
(408) 594-9400
[email protected]

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784

GlobeNewswire Distribution ID 9115418

Curia et Carterra coorganisent un symposium sur les produits biologiques pour encourager la recherche en biotechnologie dans le nord-ouest du Pacifique

ALBANY, New York et SALT LAKE CITY, 10 mai 2024 (GLOBE NEWSWIRE) — Curia, une organisation de premier plan du domaine de la recherche, du développement et de la fabrication sous contrat, et Carterra Inc., leader mondial de la découverte d’anticorps et de médicaments à petites molécules sans étiquette à haut débit, annoncent ce jour un partenariat ciblé sur l’organisation d’un symposium sur les produits biologiques à haut débit, prévu le 31 mai au Residence Inn at Marriott de Seattle, dans l’État de Washington.

L’objectif de cette collaboration vise la promotion de l’intérêt croissant suscité par la biotechnologie dans la zone nord-ouest du Pacifique des États-Unis et du Canada. Le symposium réunira des professionnels de tous niveaux de direction scientifique de la biotechnologie et de la pharmaceutique.

« Nous sommes ravis de nous associer à Carterra pour organiser ce symposium axé sur la découverte d’anticorps, qui réunira l’ensemble de la communauté biotechnologique du nord-ouest du Pacifique et permettra de partager les dernières avancées en matière de découverte d’anticorps », observe Steve Lavezoli, vice-président des produits biologiques chez Curia. Et de poursuivre : « Nous sommes également impatients d’échanger sur nos meilleurs flux de travail, de haute qualité et accélérés pour la découverte, le développement et la fabrication clinique d’anticorps en vue d’une première administration chez l’être humain. Les anticorps découverts et/ou conçus à l’aide de la plateforme technologique de Curia sont utilisés en clinique et nous avons mené avec succès plus de 230 campagnes de découverte d’anticorps au bénéfice de la communauté biotechnologique. »

La rapidité, l’expertise scientifique et l’efficacité permettent de surmonter les forts taux de rotation de la découverte précoce d’anticorps et d’assurer la mise en marché de nouveaux produits thérapeutiques. Le symposium mettra en lumière la plateforme technologique et les services intégrés de Curia, en exerçant un focus sur le développement de modèles murins améliorés pour la génération d’anticorps et le criblage de cellules B uniques à haut débit. La combinaison du séquençage de nouvelle génération (SNG) et de la production recombinante rapide de quantités d’anticorps monoclonaux (AcM) purifiés (de milligramme en gramme) accélère considérablement l’identification des approches de développement de produits candidats.

Depuis 2017, Carterra commercialise son puissant biocapteur à haut débit LSA®, conçu pour l’analyse et la caractérisation des anticorps à l’aide de la résonance plasmonique de surface (ou SPR pour Surface Plasmon Resonance). Depuis le lancement de sa plateforme LSAXT l’année dernière, Carterra propose des produits en mesure d’effectuer l’analyse de petites molécules et permettre la découverte d’anticorps. La plateforme LSA a fait l’objet de plusieurs articles évalués par des pairs dans Science, Nature et Cell, détaillant le parcours de plusieurs produits thérapeutiques faisant leur entrée dans les essais cliniques. Lors du symposium, plusieurs scientifiques renommés du secteur biopharmaceutique partageront les éclairages propres à leurs domaines spécifiques de découverte de médicaments et mettront en évidence l’effet novateur de l’intégration de la technologie HT-SPR, de l’intelligence artificielle et de l’apprentissage automatique et d’autres nouvelles technologies.

« Nous sommes enchantés de nous associer à Curia pour organiser ce symposium. Les symposiums de Carterra sont des événements scientifiques que nous organisons chaque année aux États-Unis et en Europe », précise Chris M. Silva, vice-président du marketing et des produits chez Carterra, avant d’ajouter : « Ils nous permettent de partager les dernières avancées technologiques et les données significatives générées par les flux de travail des scientifiques utilisant les plateformes sans étiquette de Carterra. Nous rendre dans le nord-ouest du Pacifique nous permettra d’induire une meilleure compréhension de la technologie applicable aux domaines pharmaceutique et biotechnologique dans cette région. »

Cliquez ici pour vous inscrire à l’événement. L’inscription est obligatoire car le nombre de places est limité.

À propos de Curia :
Curia est une organisation de développement et de fabrication sous contrat (ou CDMO pour Contract Development and Manufacturing Organization) avec plus de 30 ans d’expérience à son actif, qui exploite un réseau intégré de 27 sites à travers le monde et emploie plus de 3 500 collaborateurs travaillant en partenariat avec des clients biopharmaceutiques pour commercialiser des traitements ayant un véritable impact sur la vie des personnes. Nos offres de produits biologiques et de petites molécules vont de la découverte à la commercialisation, et intègrent des capacités réglementaires et analytiques intégrées. Nos scientifiques, nos experts en processus et nos installations de pointe apportent une expérience de premier ordre dans la fabrication de substances et de produits pharmaceutiques. De la curiosité au traitement, nous réalisons toutes les étapes pour améliorer la vie des patients. Consultez notre site à l’adresse suivante : www.curiaglobal.com.

À propos de Carterra, Inc. :
Carterra, Inc. est une société privée. Sa technologie HT-SPR délivre aux clients du secteur de la découverte de médicaments à petites et grandes molécules un débit de criblage et de caractérisation et des fonctionnalités qui s’adaptent aux applications de niveau omique, ramenant ainsi des mois de travail à quelques jours à peine. Nos solutions ont permis la mise au point de nombreux traitements et de recherches révolutionnaires. Elles ont appuyé les chercheurs universitaires et translationnels ainsi que les sociétés biopharmaceutiques spécialisés dans les domaines de l’oncologie, de l’immunologie, des neurosciences, entre autres. Carterra est domiciliée à Salt Lake City, dans l’Utah, et exploite des centres d’expérience client situés à San Francisco, Salt Lake City et Boston, ainsi qu’à Manchester, en Angleterre, et à Munich, en Allemagne. Les produits Carterra sont disponibles en Asie-Pacifique et en Océanie par l’intermédiaire de notre distributeur exclusif, Revvity. Pour en savoir plus, consultez le site www.carterra-bio.com ou retrouvez-nous sur LinkedIn ou X (Twitter).

Coordonnées Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Interlocutrice auprès des médias :
Cheri Salazar
(408) 594-9400
[email protected]

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784

GlobeNewswire Distribution ID 9115418

‫ثورة في عالم التنافس والتداول: تعاون AlphaX مع رائد سباقات فورميلا تو إنزو فيتيبالدي

سيدني، أستراليا – 10 مايو 2024 – تعلن AlphaX المنصة الرائدة في تداول العملات المشفرة، والمتخصصة في صياغة مستقبل التداول بكل فخر وضع حجر الأساس لشراكتها مع سائق سباقات فورميلا تو (F2) إنزو فيتيبالدي. هذا التعاون يميز تقاربًا قائمًا بين سباقات السرعة الفائقة وتكنولوجيا التداول العصرية ويهدف إلى هدفٍ مشتركٍ وهو الجمع بين السرعة والابتكار للفوز بالمستقبل.

وقد تأسست منصة AlphaX على الشفافية والابتكار وتقدِّم مجموعة متنوعة من حلول التداول لهواة تداول العملات المشفرة. من التداول الفوري والمشتقات المتطورة. تمد AlphaX المستخدمين بأدوات متطورة حديثة للإبحار في العالم الديناميكي للأصول المشفرة. كما استحدثت AlphaX مزايا متطورة مثل تداول الإيردروب ومكافأة المتداولين على التداول، و Snipe Meme ومحفظة أدوات لسهولة شراء الأصول الموجودة في التشين. ومن خلال هذه التطورات تواصل AlphaX إعادة صياغة تجربة التداول من جديد.

إنزو فيتيبالدي النجم الصاعد في عالم سباقات فورميلا تو وسليل أسرة فيتيبالدي الشهيرة في عالم السباقات التي تجمع بين الابتكار والتميز. في الميدان المتسارع لسباق السيارات الذي يمكن أن تحدد فيه أجزاءً من الثانية الفائز من الخاسر حيث السرعة والدقة وطريقة القيادة مهمة للغاية. هناك رؤية مشتركة بين AlphaX وإنزو فيتيبالدي إلا وهي تجاوز الحواجز واحتواء التحديات لتحقيق النجاح. تهدف AlphaX من خلال هذه الشراكة إلى إشراك قاعدة جماهيرية أوسع من خلال زيادة حب سباقات السيارات على مستوى العالم ودمجها مع العالم المثير لتداول العملات المشفرة.

وقد قال المدير التنفيذي لمنصة AlphaX نحن متحمسون لبدء هذه الرحلة الشيقة مع إنزو فيتيبالدي، فهذه الشراكة تمثل دمجًا بين السرعة والابتكار والتفوق ونحن متعطشون لإحداث ثورة عند ملتقى التسابق والتداول. فمن خلالهما معًا نمضي بخطىً حثيثة متزنة نحو المستقبل محددين معاييرًا جديدة للأداء محطمين حواجز الممكن.

ومع تأهب AlphaX و فيتيبالدي يتوقع العالم تعاونًا مثيرًا للتنافس ومحفزً للتداول ليمهد الطريق نحو مستقبل حماسي.

AlphaX

AlphaX Exchange منصة رائدة في تداول العملات المشفرة متخصصة في اكتشاف العملات المشفرة التي تركز على القيمة وتعزز هذه العملات المشفرة. ونظرًا لأن لدى الشركة أساسًا راسخًا بناه خبراء المجال والتزامًا بأمن المستخدم ورضاه، لذا فإن AlphaX هي مدخلك لمستقبل الاستثمار. انضم إلينا ونحن نواصل سبر أغوار غاية سوق العملات المشفرة، أحد أصول التداول الناجحة في عصرها.

Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 12, 2024

REGULATED INFORMATION
May 10, 2024, 7:00am CET / 1:00am ET

NYXOAH SA
(Euronext Brussels: NYXH)
Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium
(hereinafter the “Company”)

Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company
to be held on June 12, 2024

The board of directors of the Company is pleased to invite its securities holders to attend the annual shareholders’ meeting of the Company, to be held on Wednesday, June 12, 2024 at 2:00 p.m. CET at the Company’s seat, or at such other place as will be indicated prior to such time. The annual shareholders’ meeting will be followed immediately by an extraordinary shareholders’ meeting.

The Company will also set up a video conference to allow holders of securities of the Company who have duly registered for the annual and the extraordinary shareholders’ meetings to follow the meetings remotely and ask questions, as the case may be in writing, during the meetings. The modalities to attend the meetings via video conference will be communicated to the relevant securities holders in due time. The videoconference will not qualify as an electronic communication tool to attend and vote at the shareholders’ meetings as referred to in Article 7:137 of the Belgian Code of Companies and Associations, but will be an extra facility for securities holders to follow the shareholders’ meetings. Holders of securities wishing to attend the meetings via video conference and also validly vote on the items on the agendas, are invited to exercise their voting rights prior to the shareholders’ meetings by following the rules set out in this convening notice, either by voting remotely by mail, or by giving a proxy to a representative of the Company.

In order to facilitate the keeping of the attendance list on the day of the annual and the extraordinary shareholders’ meetings, the holders of securities issued by the Company and their representatives are invited to register as from 1:30 p.m. CET.

AGENDA OF THE ANNUAL SHAREHOLDERS’ MEETING

  1. Acknowledgement and discussion of:
  1. the statutory annual accounts for the financial year ended on December 31, 2023;
  2. the consolidated financial statements for the financial year ended on December 31, 2023;
  3. the annual report of the board of directors on the statutory annual accounts for the financial year ended on December 31, 2023;
  4. the annual report of the board of directors on the consolidated financial statements for the financial year ended on December 31, 2023;
  5. the statutory auditor’s report on the statutory annual accounts for the financial year ended on December 31, 2023; and
  6. the statutory auditor’s report on the consolidated financial statements for the financial year ended on December 31, 2023.

1.      Approval of the statutory annual accounts for the financial year ended on December 31, 2023 and the proposed allocation of the result

Proposed decision: The shareholders’ meeting decides to approve the annual accounts for the financial year ended on December 31, 2023 and the allocation of the result as proposed by the board of directors.

2.      Discharge of directors

Proposed decision: The shareholders’ meeting decides to grant discharge to each of the directors who was in office during the financial year ended on December 31, 2023 for the performance of their mandate during that financial year.

3.      Discharge of the statutory auditor

Proposed decision: The shareholders’ meeting decides to grant discharge to the statutory auditor who was in office during the financial year ended on December 31, 2023 for the performance of his mandate during that financial year.

4.      Acknowledgement and approval of the remuneration report

Proposed decision: The shareholders’ meeting decides to approve the remuneration report.

  1. Acknowledgement and approval of the amended remuneration policy to allow for a share-based remuneration for the non-executive directors

Upon the recommendation of the remuneration committee, the board of directors proposes to amend the remuneration policy of the Company to allow for the granting of so-called “restricted share units” or “RSUs” to non-executive directors. This RSU remuneration component replaces the existing share-based remuneration in the form of a grant of warrants to non-executive directors as approved by the annual shareholders’ meeting of June 8, 2022. The proposed features of the RSUs are summarized in the proposed amended remuneration policy.

Proposed decision: The shareholders’ meeting decides to approve (a) the amended remuneration policy, (b) the granting to non-executive directors of “restricted share units” or “RSUs” as further described in the amended remuneration policy, whereby the RSUs shall be awarded for the first time as of the date of this shareholders’ meeting, and (c) the cancellation as of the date of this shareholders’ meeting of the current warrant component of the non-executive directors’ remuneration as approved by the annual shareholders’ meeting of June 8, 2022.

  1. Appointment of Robelga SRL (permanently represented by Robert Taub) as director

Proposed decision: The shareholders’ meeting decides to appoint Robelga SRL, permanently represented by Robert Taub, as director of the Company until the annual shareholders’ meeting to be held in 2025. The mandate of Robelga SRL will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

1.      Reappointment of Jürgen Hambrecht as independent director

Proposed decision: The shareholders’ meeting decides to reappoint Jürgen Hambrecht as an independent director of the Company within the meaning of Article 7:87 of the CCA and provision 3.5 of the 2020 Belgian Corporate Governance Code, until the annual shareholders’ meeting to be held in 2025. The mandate of Jürgen Hambrecht will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

2.      Reappointment of Kevin Rakin as independent director

Proposed decision: The shareholders’ meeting decides to reappoint Kevin Rakin as an independent director of the Company within the meaning of Article 7:87 of the CCA and provision 3.5 of the 2020 Belgian Corporate Governance Code, until the annual shareholders’ meeting to be held in 2025. The mandate of Kevin Rakin will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

3.      Reappointment of Rita Johnson-Mills as independent director

Proposed decision: The shareholders’ meeting decides to reappoint Rita Johnson-Mills as an independent director of the Company within the meaning of Article 7:87 of the CCA and provision 3.5 of the 2020 Belgian Corporate Governance Code, until the annual shareholders’ meeting to be held in 2025. The mandate of Rita Johnson-Mills will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

4.      Reappointment of Virginia Kirby as independent director

Proposed decision: The shareholders’ meeting decides to reappoint Virginia Kirby as an independent director of the Company within the meaning of Article 7:87 of the CCA and provision 3.5 of the 2020 Belgian Corporate Governance Code, until the annual shareholders’ meeting to be held in 2025. The mandate of Virginia Kirby will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

5.      Reappointment of Wildman Ventures LLC (permanently represented by Daniel Wildman) as independent director

Proposed decision: The shareholders’ meeting decides to reappoint Wildman Ventures LLC, permanently represented by Daniel Wildman, as an independent director of the Company within the meaning of Article 7:87 of the CCA and provision 3.5 of the 2020 Belgian Corporate Governance Code, until the annual shareholders’ meeting to be held in 2025. The mandate of Wildman Ventures LLC will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

6.      Reappointment of Pierre Gianello as director

Proposed decision: The shareholders’ meeting decides to reappoint Pierre Gianello as director of the Company until the annual shareholders’ meeting to be held in 2025. The mandate of Pierre Gianello will be remunerated as provided for the non-executive members of the board of directors in the Company’s remuneration policy as adopted by the shareholders’ meeting and, as concerns the cash remuneration, as decided by the annual shareholders’ meeting of June 8, 2022.

7.      Reappointment of Olivier Taelman as director

Proposed decision: The shareholders’ meeting decides to reappoint Olivier Taelman as director of the Company until the annual shareholders’ meeting to be held in 2025. The mandate of Olivier Taelman will not be remunerated.

AGENDA OF THE EXTRAORDINARY SHAREHOLDERS’ MEETING

  1. Acknowledgment and discussion of the special report by the board of directors drawn up in accordance with article 7:199 of the Belgian Code of Companies and Associations relating to the proposal to renew the authorized capital

8.      Renewal of the authorization to the board of directors to increase the share capital within the framework of the authorized capital

Proposed decision: The shareholders’ meeting resolves to renew the authorization to the board of directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorization, with an aggregate amount equal to EUR 3,436,000, and this in accordance with the terms and conditions set forth in the special report of the board of directors prepared in accordance with Article 7:199 of the Belgian Code of Companies and Associations, as referred to in agenda item 1 of this extraordinary shareholders’ meeting.

Consequently, the shareholders’ meeting resolves to delete the first and second paragraph of Article 7 (“Authorized capital”) of the articles of association of the Company entirely and to replace such first and second paragraph of Article 7 respectively with the following text (whereby (i) the date referred to between brackets in the second paragraph shall be the date of the shareholders’ meeting approving the renewed authorized capital, and (ii) the other provisions of Article 7 remain in place and are re-approved):

A)   text of the first paragraph: “The board of directors is authorized to increase the capital of the company on one or several occasions in accordance with the Code of Companies and Associations by a maximum aggregate amount of EUR 3,436,000.”

B)   text of the second paragraph: “This authorization is valid for a period of five years as from the date of publication in the Annexes to the Belgian State Gazette of an extract of the minutes of the extraordinary shareholders’ meeting of the company of [date of the shareholders’ meeting approving the renewed authorized capital].”

5.      Power of attorney to the notary

Proposed decision: The shareholders’ meeting decides to grant the acting notary, and any other notary of “Berquin Notarissen”, all powers to draw up and sign a restated version of the articles of association of the Company and to file them in the appropriate data base in accordance with applicable law.

ADMISSION FORMALITIES AND PARTICIPATION IN THE SHAREHOLDERS’ MEETINGS

In order to attend the shareholders’ meetings on June 12, 2024, the holders of shares and subscription rights are requested to comply with articles 26 and 27 of the Company’s articles of association and the following formalities.

If the attendance quorum required pursuant to Article 7:153 of the Belgian Code of Companies and Associations is not met at the extraordinary shareholders’ meeting of June 12, 2024, a second extraordinary shareholders’ meeting will be convened on Monday, July 1, 2024 at 2:00 p.m. CET, to deliberate and resolve on the agenda items of the extraordinary shareholders’ meeting regardless of the share capital present or represented by the shareholders.

The holders of subscription rights issued by the Company can, in accordance with Article 7:135 of the Belgian Code of Companies and Associations only attend the shareholders’ meetings with a consultative vote.

In order to be able to participate in the annual and the extraordinary shareholders’ meetings, a holder of securities issued by the Company must satisfy two conditions: (a) be registered as holder of such securities on the registration date and (b) notify the Company, as described below.

Registration date

The registration date is May 29, 2024 at midnight (Belgian time). Only persons registered as securities holders on that date and time will be entitled to attend and (if they are shareholders) vote at the meetings. The number of securities held by the securities holder on the day of the meetings will not be taken into account.

  • Holders of registered shares or subscription rights must be registered in the Company’s share register or subscription rights register, as the case may be, by midnight (Belgian time) on May 29, 2024.
  • Holders of dematerialized shares must deliver, or have delivered, to the Company, at the latest on June 6, 2024 at midnight (Belgian time), a certificate issued by the authorized account holder or by the settlement institution certifying the number of dematerialized shares registered in the name of the shareholder in its accounts on the registration date, for which the shareholder has declared his intention to participate in the meetings. This certificate must be sent to the Company by e-mail to [email protected].

Intention to participate in the meetings

The securities holders must inform the board of directors of the Company by e-mail to [email protected] no later than June 6, 2024, of their intention to participate in the meetings, indicate the number of securities for which they intend to vote, and, for holders of dematerialized shares, present proof of their registration as a shareholder on the registration date.

In order to attend the meetings, securities holders and proxy holders must prove their identity and representatives of legal entities must submit documents establishing their identity and their power of representation, at the latest immediately before the start of the meetings.

Voting by proxy or by mail

Shareholders can exercise their voting rights prior to the meetings either (i) by voting by mail or (ii) by giving a proxy to a representative of the Company.

If shareholders vote by proxy, the proxy holder will be a representative of the Company. This proxy holder may only exercise the voting right in accordance with the voting instructions contained in the proxy.

The proxy voting form and the form for voting by mail approved by the Company must be used for this purpose. These forms can be downloaded from the Company’s website (https://investors.nyxoah.com/shareholder-information > Shareholders’ Meetings).

If shareholders vote by proxy or by mail, they must, in addition to the above formalities, send by e-mail to [email protected] a duly completed and signed proxy voting form or form for voting by mail. These documents must reach the Company no later than June 6, 2024.

Note that the proxy voting forms and the forms for voting by mail may be signed by using an electronic signature as provided for in Article 7:143 § 2 of the Belgian Code of Companies and Associations.

Participation in the virtual shareholders’ meetings

Securities holders wishing to participate remotely, virtually and in real time, to the Company’s annual and extraordinary shareholders’ meetings are required to confirm their participation and communicate their e-mail address to the Company by June 6, 2024 at the latest by e-mail to [email protected].

A few days before the shareholders’ meetings, securities holders who have completed this formality will receive by e-mail (at the address they will have communicated to the Company) a link, and as the case may be a user name and a password, enabling them to follow and participate in the shareholders’ meetings via their computer, tablet or smartphone.

Just before the start of the shareholders’ meetings, the securities holders will have to click on the link that will have been previously communicated to them by e-mail, and as the case may be enter their user name and password, in order to join the virtual shareholders’ meetings.

Securities holders attending the virtual shareholders’ meetings will have the opportunity to view the live broadcast of the meetings in real time and to ask questions to the directors, as the case may be in writing, during the meetings regarding the items on the agenda.

New agenda items, proposed decisions and right to ask questions

Shareholders holding at least 3% of the capital who wish to request the inclusion of new items on the agenda or to submit proposals for decision must, in addition to the above formalities, establish on the date of their request proof of ownership of the required participation in the capital and send the text of the agenda items and the proposed decisions by e-mail to [email protected] no later than May 21, 2024. The request must also mention the e-mail address to which the Company will send the confirmation of receipt of the request.

The case being, the revised agenda will be published no later than May 28, 2024.

Shareholders who wish to do so may send any questions they may have to the Company, relating solely to the agendas of the annual and the extraordinary shareholders’ meetings, by e-mail to [email protected], no later than June 6, 2024. The answers to these questions will be provided during the annual and the extraordinary shareholders’ meetings in accordance with applicable law.

Documentation

All documents concerning the annual and the extraordinary shareholders’ meetings that are required by law to be made available, as well as the total number of shares and voting rights outstanding, are available on the Company’s website on: https://investors.nyxoah.com/shareholder-information. The documents are also available at the seat of the Company and can only be consulted by appointment made by e-mail ([email protected]). Shareholders may also obtain a hard copy of these documents free of charge by sending an e-mail to [email protected].

The aforementioned formalities, as well as the instructions on the Company’s website and on the proxy voting forms and forms for voting by mail must be strictly observed.

Various

Quorum: There is no particular quorum requirement for the deliberation and voting of the decisions proposed in the agenda of the annual shareholders’ meeting.

In accordance with Article 7:153 of the Belgian Code of Companies and Associations, at least 50% of the share capital must be present or represented for the deliberation and voting on the decisions proposed in item 2 of the agenda of the extraordinary shareholders’ meeting.

Voting: Each share entitles the holder to one vote.

Majority: In accordance with applicable law, the decisions proposed in the agenda of the annual shareholders’ meeting and the decisions proposed in the agenda of the extraordinary shareholders’ meeting, other than agenda item 2, will be adopted if they are approved by a simple majority of the votes validly cast by the shareholders present or represented at the relevant shareholders’ meeting. In accordance with Article 7:153 of the Belgian Code of Companies and Associations, the decisions proposed in item 2 of the agenda of the extraordinary shareholders’ meeting will be adopted if they are approved by 75% of the votes validly cast by the shareholders present or represented. Blank votes and abstentions are not taken into account.

Personal data: The Company is responsible for the processing of personal data that it receives or collects from holders of securities issued by the Company and agents in connection with the Company’s shareholders’ meetings.

The processing of such data will be carried out for the purpose of organizing and holding the relevant shareholders’ meeting, including convening, registration, attendance and voting, as well as maintaining lists or registers of securities holders and for purposes of analysis of the Company’s securities holders’ base.

The data includes, but is not limited to, the following: identification data, the number and nature of a holder’s securities issued by the Company, proxies and voting instructions. This information may also be transferred to third parties for the purpose of assisting or servicing the Company in connection with the foregoing.

The processing of such data will be carried out, mutatis mutandis, in accordance with the Company’s privacy notice available on the Company’s website: https://www.nyxoah.com/privacy-notice-nyxoah.

The Company draws the attention of holders of securities issued by the Company and agents to the description of the rights they may have as data subjects, such as, inter alia, the right of inspection, the right to rectify and the right to object to processing, which are set out in the section entitled “What rights can you exercise?” of the aforementioned privacy notice.

All this is without prejudice to the applicable rules on registration, use of information and participation in shareholders’ meetings in order to exercise your rights as a data subject. For any other information relating to the processing of personal data by or on behalf of the Company, the Company can be contacted by e-mail at [email protected].

The board of directors

Attachment

GlobeNewswire Distribution ID 1000949955

‫الجديد الرائد إنفيكس جي تي 20 برو فلاجشيب (Infinix GT 20 Pro): الهاتف الثوري في عالم الرياضة الإلكترونية، والخطوة الأولى نحو عالم الألعاب الشامل

الرياض، المملكة العربية السعودية، 10 مايو 2024 – تعلن إنفينكس، العلامة التجارية التقنية العصرية التي تستهدف بمنتجاتها المستهلكين الشباب، عن إطلاق هاتفها المتطور المخصص للألعاب والذي يتميز بمعالج ذي شريحتين بنسخته النهائية. إنه هاتف إنفيكس جي تي 20 برو؛ الهاتف الذكي الوحيد الذي يوفر رقاقة عرض مخصصة للألعاب في نطاق سعره، ويتميز بأدائه المميز الذي يلبي مستوى الرياضة الإلكترونية؛ وبذلك فإنه ينقل تجربة الألعاب المحمولة عبر الأجهزة والبرامج إلى آفاق جديدة.

يعبّر ويكي ني، رئيس المنتجات في إنفينكس عن حماسه حول هذا الهاتف قائلاً: “عندما يلتقي الشغف مع التكنولوجيا، فإنهما يعزفان ألحان الابتكار الذي لا حدود له. إن نجاح إنفيكس جي تي 20 برو لم يكن سوى البداية، واللحنَ الأول في سيمفونية عريقة من الأجهزة، والبرامج، وأنظمة التبريد، وتصميم السايبر-ميكا الأمني، التي تنقل عالم الهواتف إلى آفاق جديدة. إنه ليست مجرد هاتف؛ إنه نقطة تحول في عالم البطولات في الرياضة الإلكترونية المحترفة”.

كما أن إطلاق إنفينكس جي تي فيرس (Infinix GT VERSE) يرفع مستوى الألعاب، من خلال إصدار مجموعة من المنتجات تلبي متطلبات اللعب بما في ذلك كمبيوتر محمول، وسماعات أذن، وساعة ذكية، ومروحة تبريد.

تفوّق على الهواتف الأخرى

يضم الهاتف معالج Dimensity 8200 Ultimate  بتقنية 5G وتصنيع 4 نانومتر، ورقاقة عرض الألعاب المخصصة Pixelworks X5 Turbo؛ مما يجعله هاتفًا ثوريًا يوفر أداءً يلبي مستوى الرياضة الإلكترونية. كما أن زيادة معدلات الإطار من 60 إطارًا في الثانية إلى 120 إطارًا في الثانية، توفر تجارب بصرية مذهلة. سيخوض اللاعبون تجربة ألعاب آسرةً ويستمتعون بتفاعل مميز من خلال هذا الهاتف؛ فهو أول هاتف ذكي معتمد بواسطة برنامج الشهادة المعتمدة IRX تطلقه شركة إنفينكس.

أداء خارق يجعله وحش الألعاب بلا منازع

كما أنه مزوّد بميزة إكس بوست (Xboost) لإدارة الأداء المستدام، ويستخدم المزامنة العمودية لمنع تمزق الشاشة. أما عند الحديث عن المحرك، فيتميز بأنه يعطي أولويةً لموارد الألعاب، مما يضمن تجربة ألعاب سلسة وذات أداء مميز.

يتميز نظام التبريد في الهاتف بأنه نظام مصمم بعناية يستخدم ورقة الجرافيت لمادة متغيرة الطور (PCM) بحجم 68% أكبر، ونظام تبريد سائل VC بحجم 73% أكبر لتحسين كفاءة التبريد وتبديد الحرارة، كما يتم تطبيق أكثر من 66% من معجون الحرارة على المنطقة التي تشكل مصدر الحرارة الأساسية للتبريد المستهدف.

على الرغم من أن سلسلة هواتف إنفينكس جي تي (Infinix GT) دخلت حديثًا إلى ساحة الهواتف الرائدة في عالم الألعاب، إلا أنها تمكنت في غضون عام واحد فقط من أن تتألق وتصبح علامة فارقة في مجال

تسعى شركة إنفينكس إلى توفير تجربة ألعاب مميزة للمستخدمين؛ تجربةً تليق بمستوى الرياضات الإلكترونية. وأخيرًا وبعد أن أخضعت الشركةُ هاتف إنفيكس جي تي 20 برو إلى ثلاث جولات من الاختبارات الاحترافية الصارمة، أثبت جدارته واستوفى المعايير المطلوبة لاستخدامه على مستوى البطولات وأصبح الهاتف الرسمي لبطولة ببجي موبايل سوبر ليج (PMSL).

يقدم هاتف إنفيكس جي تي 20 برو أداءً استثنائيًا ويُظهر كفاءة في التعامل مع الألعاب الشهيرة كلعبة موبايل ليجيندز (MLBB)، وببجي (PUBG)، وكول أوف ديوتي (COD)، وجينشين إمباكت (Genshin Impact) وهونكاي: ستار رايل (Honkai: Star Rail). كما يمكنه رفع معدلات تحديث لعبة جينشين إمباكت إلى 120 هرتز من خلال التداخل ليوفر تجربة لعب سلسة ولا مثيل لها.

هاتف مصمم ليتفوق في عالم الألعاب

يتيمز هاتف إنفيكس جي تي 20 برو بتصميم السايبر-ميكا الذي يتماشى مع تصور إنفينكس جي تي للمعدن، والقوة، والسرعة. كما يتمتع بنمط شفرة التوربين الفريد مما يمنحه جمالًا ديناميكيًا وأداءً مميزًا. توفر واجهته ميكا لووب ليد (Mecha Loop LED) تخصيصًا واسعًا، مع ثمانية تركيبات للألوان وأربعة تأثيرات إضاءة؛ مما يتيح للاعبين تخصيصًا شاملًا لأجهزتهم. إن تصميمه الخارجي مستوحىً من البنية المعقدة لخلايا النحل، ويتماشى مع التصميمات الجميلة والنابضة بالحياة للألعاب الحديثة؛ مما يجعله الخيار الأمثل للاعبين الباحثين عن الأداء والأناقة معًا.

المزايا الرئيسية

  • شاشة المصفوفة العضوية النشطة ذات الصمام الثنائي الباعث للضوء (AMOLED) مقاس 6.78 بوصة بدقة عرض كاملة محسّنة (FHD+) ومعدل تحديث 144 هرتز بحواف رفيعة.
  • نظام التشغيل النقي والنظيف Clean & Pure OS 2.0 مع تحديثين رئيسيين لنظام أندرويد وتحديثات أمان لمدة 3 سنوات.
  • سماعات مزدوجة بتقنية صوت ماركة JBL.
  • وضع الشحن السريع – بطارية بسعة 5000 مللي أمبير وشحن سريع بقوة 45 واط.
  • تصميم سايبر-ميكا بوجود إضاءة ميكا لووب ميني ليد (Mecha Loop Mini LED) قابلة للتخصيص والتفاعل.
  • تأثيرات إضاءة الألعاب ميكا لووب.

كاميرا خلفية ثلاثية بدقة 108 ميجابكسل مزودة بتقنية تثبيت الصور الضوئي (OIS).

كما يسر شركة إنفينكس أن تعلن أيضًا عن كومبيوترها المحمول الجديد إنفينكس جي تي بي بوك (Infinix GTBOOK) الذي تم إنشاؤه بالتعاون مع شركة إنفيديا (Nvdia). يتميز هذا الكومبيوتر بتقنية وحدة المعالجة المركزية، ووحدة معالجة الرسومات المتطورة، وحلول تبريد متقدمة، وشاشة عالية معدل التحديث. تتزين هذه الميزات بتصميم أنيق يعكس التزام منتجات سلسلة إنفينكس جي تي بتصميمات تحاكي جماليات الألعاب الحديثة والتي يكون اللاعب حجر الأساس فيها.

هاتف الألعاب الرسمي لبطولة ببجي موبايل سوبر ليج

(PMSL)أصبح هاتف إنفيكس جي تي 20 برو هاتف الألعاب الرسمي لبطولة ببجي موبايل سوبر ليج

السعر والتوفر:

سيتوفر هاتف إنفيكس جي تي 20 برو باللون الأزرق الميكا، والبرتقالي الميكا، والفضي الميكا، بإعدادات ذاكرة 12+256 جيجابايت و8+256 جيجابايت. أما الأسعار فستختلف حسب المنطقة، وسيتم الإعلان عن التفاصيل عند إطلاق الهاتف

نبذة عن إنفينكس:

إنفينكس موبايليتي هي علامة تجارية تكنولوجية ناشئة تختص بتصميم وتصنيع وتسويق مجموعة متنامية من الأجهزة حول العالم التي تحمل علامة إنفينكس التي تأسست في عام 2013. تستهدف إنفينكس المستهلكين من فئة الشباب، وتصبّ اهتمامها على تطوير تكنولوجيا حديثة متقدمة تتمثل في أجهزة الهواتف المحمولة المصممة بعناية التي تتميز بطرازها الراقي، وكفاءتها العالية، وأدائها المميز. وقد اتصفت أجهزة إنفينكس بكونها عصرية ومتاحة للجميع، وتلبي احتياجات المستخدم النهائي؛ فهو جوهر كل خطوة من خطوات التطوير.

لمزيد من المعلومات، يرجى زيارة: http://www.infinixmobility.com

Infinix GT 20 Pro Flagship Launch: Esports-Level Gaming Phone Revolution and the Dawn of a Holistic Gaming Universe

RIYADH, SAUDI ARABIA – Media OutReach Newswire – 9 May 2024 – Infinix, a trendy tech brand crafted for young consumers, announces its ultimate dual-chip gaming phone, the Infinix GT 20 Pro. Being the only smartphone to offer a dedicated gaming display chip at its price point, it delivers esports-level performance, redefining the mobile gaming experience across hardware and software.
Infinix GT 20 Pro Flagship Launch

Weiqi Nie, Head of Product at Infinix excitedly shares, “Innovation knows no bounds when passion meets technology. The success of the Infinix GT 10 Pro was just the beginning. With the Infinix GT 20 Pro, we have raised the bar higher, introducing a symphony of hardware, software, cooling systems, and cyber-mecha design. It’s not just a phone; it’s a game-changer for professional esports tournaments.”

Furthermore, the introduction of the Infinix GT VERSE elevates gaming, creating a range of products including a laptop, earphones, a smartwatch, and a cooling fan.

Outplay The Rest
The Infinix GT 20 Pro sets itself apart in its price segment with dual chips that bring its performance on par with competitive flagship processors, delivering an unmatched high-performance gaming experience. Featuring the Dimensity 8200 Ultimate 4nm 5G Processor and Pixelworks X5 Turbo Dedicated Gaming Display Chip, it offers esports-level performance and visually stunning experiences, pushing frame rates from 60 FPS to 120 FPS. As the first IRX-certified smartphone launched by Infinix, players can expect a distinctively more immersive gaming experience.

Perform Like A Gaming Beast
The gaming performance of the Infinix GT 20 Pro is underpinned by a Stable Frame-rate Engine that optimizes gameplay by balancing temperature and power consumption, ensuring smooth performance with minimal power usage. It includes Xboost for sustained performance management and employs vertical synchronization to prevent screen tearing. The engine prioritizes gaming resources, guaranteeing a seamless and efficient gaming experience.

A meticulously engineered cooling system employs a 68% larger Phase Change Material (PCM) graphite sheet and a 73% larger VC Liquid Cooling system to improve cooling and heat dissipation efficiency. Additionally, more than 66% of the thermal paste is applied to the primary heat source area for targeted cooling.

The Infinix GT Series is a newcomer in the gaming flagship arena but has quickly become a shining star in the esports field within just one year. Infinix aims to provide users with an esports-level gaming experience, so after three rounds of rigorous professional testing, the Infinix GT 20 Pro has met the standards for tournament-level use and has become the Official Gaming Phone of the PUBG Mobile Super League (PMSL).

The Infinix GT 20 Pro demonstrates exceptional performance and efficiency when handling popular games including MLBB, PUBG, COD, Genshin Impact, and Honkai: Star Rail. Notably, it can upscale Genshin Impact refresh rates to 120Hz through interpolation for super-smooth gameplay.

Designed For Gaming Master
The Infinix GT 20 Pro showcases the Cyber Mecha Design, capturing the Infinix GT spirit of Metal, Power, and Speed with a unique Turbine Blade Pattern for dynamic, high-performance aesthetics. Its Mecha Loop LED Interface offers extensive customization, with eight color combinations and four lighting effects, allowing gamers to personalize their device extensively. Inspired by the intricate structure of beehives, the exterior design aligns with modern gaming’s vibrant aesthetics, making it a standout choice for gamers seeking performance and style.

Key Features
• Bezel-Less 6.78-inch 144Hz FHD+ AMOLED Display
• Clean & Pure OS 2.0 with 2 Major Android Upgrades and 3-year Security Patch Updates
• Dual Speakers with Sound by JBL
• Hyper Charge Mode – 5000mAh Battery & 45W Fast Charge
• Cyber Mecha Design with Customizable & Interactive Mecha Loop Mini LED
• Mecha Loop Game Lighting Effects
• 108MP OIS Triple Rear Camera

Vision Toward A Holistic Gaming Universe
The Infinix GT series was created to satisfy the multifaceted desires of gamers, from gameplay to enabling self-expression and beyond. The Infinix GT 20 Pro builds upon this rich heritage as part of a wider portfolio, introducing the Infinix GT VERSE, Infinix’s gaming ecosystem for all gaming enthusiasts. It features a laptop, earphones, a smartwatch, and a cooling fan, providing a full suite of tools to level up gaming.

Infinix also announces the Infinix GTBOOK, created in in collaboration with Nvdia. It boasts top-tier CPU and GPU technology, advanced cooling solutions, and a high refresh rate display. These features are encompassed within a sleek design that reflects the Infinix GT series’ commitment to cutting-edge, gamer-centric aesthetics.

Official Gaming Phone for PUBG Mobile Super League
The Infinix GT 20 Pro is the Official Gaming Phone for the PUBG Mobile Super League (PMSL). The tournament is set to take place from May 15 to June 9 in Europe, the Middle East, and Africa (EMEA), and from May 22 to June 16 in Central and South Asia (CSA). Infinix is committed to empowering all gamers with essential tools for the ultimate gaming experience.

Pricing & Availability:
The Infinix GT 20 Pro will be available in Mecha Blue, Mecha Orange, and Mecha Silver, with 12+256GB and 8+256GB memory configurations. Pricing will vary by region, with details to be announced at launch.

About Infinix:

Infinix Mobility is an emerging technology brand that designs, manufactures and markets an expanding portfolio of devices worldwide under the Infinix brand which was founded in 2013. Targeting young consumers, Infinix focuses on developing cutting-edge technology embodied in meticulously designed mobile devices that offer refined style, power and performance. Infinix devices are trendy & attainable with the end-user at the forefront of every step forward.

For more information, please visit: http://www.infinixmobility.com/

Abdullah bin Zayed, Turkish FM discuss strengthening bilateral relations; regional de-escalation efforts


ABU DHABI: H.H. Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs, hosted Hakan Fidan, Minister of Foreign Affairs of the Republic of Trkiye, for a working dinner in Abu Dhabi.

During the meeting, the two top diplomats discussed the dangerous developments in the Middle East region and the efforts of the international community to reach a sustainable ceasefire and strengthen the humanitarian response to the needs of civilians in the Gaza Strip.

H.H. Sheikh Abdullah stressed the importance of intensifying efforts at the regional and international levels to reach a ceasefire and protect the security and safety of all civilians, noting that the escalating tension, extremism, and violence in the region threaten international peace and security.

He further emphasised the critical importance of close collaboration to ensure uninterrupted and ample humanitarian assistance for civilians in the Gaza Strip, while redoubling efforts to mitigate the suffering of the brotherly people of Palestine.

In a r
elated context, the two ministers discussed the relations of friendship and strategic partnership between the two countries, focusing on the diverse development opportunities available for their peoples. The two sides also reviewed bilateral cooperation in all fields, including economic, commercial, and investment fields.

H.H. Sheikh Abdullah praised the steady growth in the volume of non-oil trade between the two countries, which increased by 103.7% in 2023, with Trkiye’s share in the UAE’s total foreign trade rising to 5.1% to become the fastest growing among the Emirates’ top 10 trading partners.

‘This significant development in non-oil trade exchange is the result of the Comprehensive Economic Partnership Agreement signed by the two countries on March 3, 2023, which entered into force on September 1st of the same year,’ Sheikh Abdullah said, stressing on the importance of continuing joint work to further strengthen relations of cooperation and partnership in all fields.

He also affirmed that the two co
untries enjoy strong and growing relations and are looking forward to establishing advanced and prosperous paths of cooperation that support their efforts to achieve comprehensive and sustainable economic growth.

Source: Emirates News Agency